Stage IVA Prostate Cancer AJCC v8 Clinical Trials
50 clinical trials for Stage IVA Prostate Cancer AJCC v8 across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE1
- High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma — RECRUITING · NA
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer — RECRUITING · PHASE3
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer — RECRUITING · PHASE2
- Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy — RECRUITING · PHASE1
- Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
- Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
- Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer — RECRUITING · NA
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial — RECRUITING · PHASE3
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer — RECRUITING · PHASE2
- Vitamin D for Prostate Endocrine Therapy — RECRUITING · PHASE3
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer — RECRUITING · PHASE3
- Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring — RECRUITING · PHASE2
- Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers — ACTIVE_NOT_RECRUITING · PHASE2
- ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy — ACTIVE_NOT_RECRUITING · PHASE2
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring — COMPLETED · PHASE1
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial — ACTIVE_NOT_RECRUITING · PHASE3
- Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial — ACTIVE_NOT_RECRUITING · PHASE3
- PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE3
- DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
- 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
- PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
- Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
- Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer — TERMINATED · PHASE2
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy — ACTIVE_NOT_RECRUITING · PHASE3
- Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
- Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) — ACTIVE_NOT_RECRUITING · PHASE2
- Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes — COMPLETED
- Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer — TERMINATED · PHASE1
- Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones — TERMINATED · PHASE2
- 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression — TERMINATED · PHASE1
- Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer — WITHDRAWN · PHASE2
- Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
- Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer — COMPLETED · PHASE1
- Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy — TERMINATED
- Gallium-68 PSMA-11 PET in Participants With Prostate Cancer — WITHDRAWN · PHASE2
- A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
- Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer — TERMINATED · PHASE2
- Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer — COMPLETED · PHASE1
- Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer — TERMINATED · PHASE2
- Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion — COMPLETED · PHASE1
- 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy — TERMINATED · PHASE2
- Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer — WITHDRAWN · PHASE1
- Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer — TERMINATED · PHASE1
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer — COMPLETED · PHASE2
- Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study — WITHDRAWN · PHASE2
Refine this search